We report an 18-year-old 46,XY phenotypic girl who has been on alternate-day dexamethasone therapy for 10 years. The patient was seen at our hospital for right-sided inguinal hernia at the age of 4 years. Biopsy of the herniated gonad showed testicular tissue, and the karyotype of the peripheral lymphocytes was 46,XY. The diagnosis of 17a-hydroxylase deficiency was established by the evaluation of adrenal steroidogenesis at the age of 6.1 years when hypertension was clearly recognized, and was confirmed later by the gene analysis of CYP17 which disclosed a compound heterozygote. The growth rate was suppressed during the initial treatment with daily administration of 0.25-0.5 mg dexamethasone.
17a-HYDROXYLASE deficiency is one of the rare forms of congenital adrenal hyperplasia.
It is caused by a deficiency of p450 17a, (CYP17) which catalyzes both 17a-hydroxylase and 17,20-lyase reactions.
The gene for this enzyme is located on chromosome 10 [1] and expressed both in the gonad and the adrenal cortex. Since the first report by Biglieri et al. [2] , more than 120 cases of this disorder Received: October 3, 1997 Accepted: December 16, 1997 Correspondence to: Dr. Mani SATOH, First Department of Pediatrics, Toho University
School of Medicine, 6-11-1 Ohmorinishi, Ohta-ku, Tokyo 143-8541, Japan have been reported [3] . Since After these studies, the left inguinal gonad was also removed.
The external genitalia were phenotypically female but looked immature.
The vagina ended at 2 cm in depth. The treatment was initiated with daily administration of 25 mg of hydrocortisone (29.4 mg/m2) at the age of 6.3 years. Although the dose was increased to 35 mg/day (41.2 mg/m2), blood pressure remained high. Therefore, treatment with daily dexamethasone at a dose of 0.5 mg (0.56 mg/ m2) was started at the age of 6.4 years, and was followed by normalization of blood pressure. A decrease in the dose of dexamethasone to 0.25 mg/ day (0.28 mg/m2) was effective in controlling blood pressure and adrenal function to within the normal ranges. Growth retardation was observed after the start of treatment with daily dexamethasone as shown in Fig. 1 . Changes in growth were plotted on the Japanese standard for girls ( Fig. 1a ) and for boys (Fig. 1b) . In order to restore growth velocity, alternate-day administration of dexamethasone was attemped at the age of 7.2 years with an initial dose of 0.25 mg (0.28 mg/m2) followed by an increase to 0.375 mg (0.39 mg/m2). Since this treatment resulted in increased plasma levels of deoxycorticosterone (DOC) and corticosterone and decreased PRA, the dose was increased to 0.5 mg (0.52 mg/m2) at the age of 8.1 years. Since this change the patient has had normal blood pressure and adrenal function, despite a gradual decrease in the relative dexamethasone dose to 0.32 mg/ m2. Height velocity dramatically improved after the introduction of alternate-day therapy. Although height velocity remained normal during the first two years of alternate-day therapy, the growth rate was again reduced at the age of 9 years. The body mass index was 16.5-18.9 and obesity did not occur during the course of dexamethasone treatment. The bone age, evaluated with Tanner-Whitehouse 2 RUS scoring system standardized for either Japanese girls or boys [4] , was retarded. Estrogen replacement therapy was started with 3.5 , tg/day of conjugated estrogens at the age of 11.1 years. Thereafter, the estrogen dose was increased gradually to 1.25 mg/day as shown in Fig. 1 and breast development had reached Tanner stage 4 by the age of 15 years. The growth rate significantly increased after estrogen was increased to 62.5 ug/ day. At an estrogen dose of 625 jig the height velocity reached the peak value of 7.5 cm/year which was close to the mean peak height velocity for Japanese girls. Stanozolol (0.5 mg/day) was introduced at the age of 14.8 years. After the dose was increased to 1.0 mg/day, growth of pubic hair appeared, but no other androgen effects were evident. The height became 166.6 cm at 18 years of age and the patient is still gradually growing and approaching the target height as a boy which is 169 cm (Fig. 1) . At the age of 15.9 years, the diurnal variation in adrenal hormone levels was studied for two consecutive days to evaluate the effect of alternateday dexamethasone therapy (0.32 mg/m2). As shown in Table 2 , plasma ACTH and corticosterone increased only before the next dexamethasone adminsitration, when the plasma dxamethasone concentration should be at its nadir. Plasma DOC and PRA remained unchanged. Analysis of the CYP17 gene revealed a compound heterozygote.
One mutation was a single base deletion (CTT to CT) at codon 247 in exon 4 which resulted in premature stop (TGA) at codon 267 and the other was a missense mutation (CAC to CTC) at codon 373 causing His 373 Leu substitution in exon 6. pubertal development and/or hypertension. Although hypertension seems to develop during childhood as shown in the present case, it is seldom recognized at young ages, since blood pressure is not necessarily measured routinely in pediatric practice. In the present case, hypertension was recognized in childhood during careful follow-up after development of Kawasaki disease. Furthermore, herniation of the gonad also gave us another chance to perform detailed studies for the diagnosis of the underlying disorder.
ACTH stimulation test undergone at the age of 6.1 years was essential for the diagnosis of 17a-hydroxylase deficiency. Moreover, molecular genetic study added a more direct confirmation. Expression studies of this particular type of compound heterozygote are now under way. Although in most cases of this disorder increased production of DOC in the zona fasciculata results in suppression of both PRA and aldosterone production in zona glomerulosa [5, 6] , the aldosterone level was not suppressed in the present case. Similar findings have also been reported in this disorder particularly from Japan [3] , but the exact mechanisms of this aldosterone production are still unknown.
It is of note that adrenal crisis is unusual despite impaired cortisol production in 17a-hydroxylase deficiency. Only four cases of adrenal insufficiency have been reported associated with this disorder [7] [8] [9] [10] . Indeed, the episode of adrenal insufficiency was not present in our patient even on the occasion of Kawasaki disease or the operation for inguinal hernia.
In patients with 17a-hydroxylase deficiency, ACTH level increases because of impaired cortisol production in the zona f asciculata, and high plasma ACTH in turn stimulates the production of corticosterone as well as DOC in the zona fasciculata. Since corticosterone has significant glucocorticoid effects, adrenal crisis seems to be unusual.
As shown in Table 2 , ACTH and corticosterone levels increased just before the next dexamethasone administration during alternate-day regimen. This implies that, at the time of decreased dexamethasone, increased corticosterone is likely to work as a "back-up" glucocorticoid, so that alternate-day dexamethasone administration can be considered a safe and unique treatment for 17a-hydroxylase deficiency.
To our knowledge, growth patterns of children with 17a-hydroxylase deficiency have not been reported whether with or without treatment. Nevertheless, it is presumed that the final height of the untreated patients with the complete type of this disorder will become tall, because the epiphyseal fusion does not occur in the absence of estrogen [11] . Indeed, this assumption was proved by an analysis of the previously reported cases [5, 8, [12] [13] [14] [15] [16] [17] . Their mean adult height SD scores calculated with the standard in each corresponding country was close to the mean for healthy males and much higher than that for females irrespective of their karyotype (Fig. 2) . This tallness, however, is an unacceptable outcome not simply because of being too tall for girls but because of persistent hypertension and absent sexual development which have been left untreated.
On the other hand, it is also of great concern to us that glucocorticoid therapy, if it is introduced in childhood, may cause growth impairment. The present case, in fact, showed a remarkable growth deceleration during the therapy with daily 
